Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 113, Issue 7, Pages 1010-1019
Publisher
Springer Nature
Online
2015-09-16
DOI
10.1038/bjc.2015.319
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
- (2015) S. Arena et al. CLINICAL CANCER RESEARCH
- ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
- (2014) Carlos L. Arteaga et al. CANCER CELL
- Biomarkers for Predicting the Efficacy of Anti-Epidermal Growth Factor Receptor Antibody in the Treatment of Colorectal Cancer
- (2014) Yasuyuki Okada et al. DIGESTION
- Cetuximab-Induced MET Activation Acts as a Novel Resistance Mechanism in Colon Cancer Cells
- (2014) Na Song et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- ERBB3/HER2 Signaling Promotes Resistance to EGFR Blockade in Head and Neck and Colorectal Cancer Models
- (2014) L. Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Co-Expression of HER Family Members in Patients with Dukes’ C and D Colon Cancer and Their Impacts on Patient Prognosis and Survival
- (2014) Said Abdullah Khelwatty et al. PLoS One
- Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer
- (2014) S. Misale et al. Science Translational Medicine
- Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma
- (2013) Jean-Pierre Delord et al. EUROPEAN JOURNAL OF CANCER
- Prognostic significance and targeting of HER family in colorectal cancer
- (2013) Helmout Modjtahedi Frontiers in Bioscience-Landmark
- Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3
- (2013) Toni M. Brand et al. PLoS One
- Therapeutic application of monoclonal antibodies in cancer: advances and challenges
- (2012) H. Modjtahedi et al. BRITISH MEDICAL BULLETIN
- Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function
- (2012) J. T. Garrett et al. CLINICAL CANCER RESEARCH
- FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk
- (2012) Alexandros Garouniatis et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
- (2012) Clara Montagut et al. NATURE MEDICINE
- EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer
- (2011) A Ålgars et al. BRITISH JOURNAL OF CANCER
- Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies
- (2011) J. Cho et al. CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors
- (2011) Luis G. Paz-Ares et al. JOURNAL OF CLINICAL ONCOLOGY
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
- (2011) K. Yonesaka et al. Science Translational Medicine
- Panitumumab – an effective long-term treatment for patients with metastatic colorectal cancer and wild-type KRAS status
- (2010) Elena Elez et al. CANCER TREATMENT REVIEWS
- HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation
- (2010) D. Liska et al. CLINICAL CANCER RESEARCH
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities
- (2009) Helmout Modjtahedi et al. ANTI-CANCER DRUGS
- Integration of panitumumab into the treatment of colorectal cancer
- (2009) Cristina Gravalos et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Panitumumab: Human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer
- (2008) Mei Wu et al. CLINICAL THERAPEUTICS
- Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer
- (2008) Amit Kumar et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
- (2008) D L Wheeler et al. ONCOGENE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started